Highest-materiality recent filing
William Turner steps down as Chief Regulatory Officer, becomes Special Advisor for Regulatory Affairs effective August 3, 2026.
FDA grants accelerated approval for Vera's TRUTAKNA (atacicept) in IgA nephropathy
FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
Vera Therapeutics stockholders elect three Class II directors, ratify KPMG, approve say-on-pay
Michael M. Morrisey elected with 45.3M For, 13.8M Withheld; Patrick G. Enright with 54.7M For; James R. Meyers with 58.9M For.
Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7
Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.
Vera Therapeutics appoints Christopher Hite to Board of Directors
Christopher Hite appointed as Class III Director effective March 5, 2026.
Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.
Vera Therapeutics Announces Departure of Chief Legal Officer Jason Carter
Jason Carter will cease to be Chief Legal Officer of Vera Therapeutics, effective December 24, 2025.
Vera Therapeutics prices public offering of 6.14M shares at $42.50, raising ~$260.9M
Entered underwriting agreement Dec 9 to sell 6,138,108 shares of common stock at $42.50/share.
Vera Therapeutics appoints James R. Meyers to Board of Directors
James R. Meyers appointed as Class II Director effective Nov 25, 2025; term expires at 2026 annual meeting.
Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).
Vera Therapeutics Q3 net loss $80.3M; atacicept BLA submission on track for Q4 2025
Net loss $80.3M ($1.26/sh) vs $46.6M ($0.85) in Q3 2024; cash & securities $497.4M.
Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025
Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.
Vera Therapeutics enters $200M at-the-market equity offering agreement with TD Cowen
New Sales Agreement with TD Cowen to sell up to $200M of Class A common stock from time to time.
Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw
Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.
Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction
Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.
Elected three Class I directors (Fordyce, Seidenberg, Hall) each with >49M votes for, ~5.4M withheld, and 1.8M broker non-votes.
Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025
Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.
Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025
Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.
Vera Therapeutics releases corporate presentation at J.P. Morgan Healthcare Conference
Updated corporate presentation furnished as Exhibit 99.1, available on company website.
Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done
Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.
Vera Therapeutics launches $300M public offering of 7.1M shares at $42.00
7,142,858 shares offered at $42.00/share; gross proceeds ~$300M before discounts and expenses.
Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M
Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.
Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies
ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.
Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.
Appoints David Johnson as COO effective July 1, 2024
David Johnson named COO; previously Chief Commercial Officer at Global Blood Therapeutics.
Vera Therapeutics appoints Christy Oliger to board; grants 25K share options
Christy Oliger appointed as Class III Director effective June 7, 2024, term through 2027 annual meeting.
Vera Therapeutics stockholders re-elect two Class III directors; ratify KPMG as auditor
Andrew Cheng re-elected with 27.4M votes for, 13.0M withheld; Scott Morrison with 31.6M for, 8.8M withheld.
Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track
Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.
Vera Therapeutics FY23 net loss $96.0M; raises $287.5M; Phase 3 on track
FY 2023 net loss $96.0M ($2.25 diluted EPS) vs $89.1M ($3.35) prior year; no revenue.
Vera Therapeutics announces $250M public offering of 8.1M shares at $31.00 per share
Offering of 8,064,517 shares of Class A common stock at $31.00/share; gross proceeds ~$250.0M.
Vera Therapeutics reports preliminary cash of $160.7M; suspends ATM offering
Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2023: approximately $160.7 million.
Vera Therapeutics reports positive 72-week Phase 2b atacicept data with eGFR stabilization in IgAN
Atacicept 150mg for 72 weeks: 62% reduction in Gd-IgA1, hematuria to 19%, 48% reduction in UPCR (PP analysis).
Vera Therapeutics posts updated corporate presentation on January 8, 2024
Exhibit 99.1 furnished under Item 7.01; no specific financial or operational details disclosed in the filing.
Vera Therapeutics appoints new CMO and CDO; prior CMO departed
Dr. Celia Lin separated as CMO effective Jan 3, 2024; received target 2023 bonus and severance.
Vera Therapeutics draws $25M in new term loans from Oxford Finance
Total borrowings under the Loan Agreement now $50M, after draws of $5M (Dec 2021), $20M (Nov 2022), and this $25M.
Vera Therapeutics Q3 net loss $20.1M ($0.45/diluted); cash $159.9M; hematuria resolution data at ASN
Net loss of $20.1M ($0.45 per diluted share) vs $24.7M ($0.91) in Q3 2022.
Vera Therapeutics Q2 net loss $20.2M, cash $181M; Phase 3 atacicept trial initiated
Net loss of $20.2M ($0.46 per share) vs $14.9M ($0.55 per share) in Q2 2022.
Vera's atacicept shows 43% placebo-adjusted proteinuria reduction at week 36 in Phase 2b IgAN trial
Atacicept 150 mg achieved 43% placebo-adjusted UPCR reduction (PP, p=0.003) and 35% (ITT, p=0.012).
Vera Therapeutics annual meeting elects three Class II directors, ratifies KPMG
Elected Maha Katabi, Ph.D., Michael M. Morrissey, Ph.D., and Patrick G. Enright as Class II directors to serve until 2026.
Vera Therapeutics reports Q1 net loss of $30.1M; atacicept Phase 3 to start Q2 2023
Net loss of $30.1M ($0.80 per diluted share) vs $17.1M ($0.71) in Q1 2022.
Positive interim Phase 2b ORIGIN data: 41% mean proteinuria reduction vs baseline at 24 weeks in 150mg dose.
Vera Therapeutics discloses minimal exposure to Silicon Valley Bank failure
Company holds approximately 1.2% of its cash and investments at SVB.
Vera Therapeutics announces $100M follow-on public offering of 14.3M shares at $7.00/share
Underwriting agreement signed for 14,285,715 shares of Class A common stock at $7.00 per share.
Vera Therapeutics reports preliminary cash of $114.7M as of Dec 31, 2022
Preliminary unaudited cash, cash equivalents and marketable securities total approximately $114.7 million at Dec 31, 2022.
At Week 24, atacicept 150 mg achieved 41% mean reduction in proteinuria and 34% delta vs placebo (p=0.025).
Vera Therapeutics reports positive Phase 2b ORIGIN topline: primary endpoint met in IgA nephropathy
UPCR reduced 31% with pooled 75/150 mg dose (p=0.037 vs placebo) and 33% with 150 mg (p=0.047) at week 24.
Vera Therapeutics Q3 net loss $24.7M; cash $114.4M; atacicept Ph2b ORIGIN data early Q1 2023
Net loss of $24.7M ($0.91 per share) vs $7.6M loss YoY; cash burn $46.4M YTD.
Vera Therapeutics restructures Novartis license milestone payments, issues ~$7M in stock
Amended license with Novartis for MAU868; capped total milestone payments at $62.0M.
Vera Therapeutics Q2 net loss $14.9M, cash $131.9M; Phase 2b atacicept enrollment complete
Net loss of $14.9M ($0.55 per share) vs $3.4M ($0.33) in Q2 2021.
On July 1, 2024, Vera Therapeutics, Inc. (the “ Company ”) announced the appointment of David Johnson as the Company’s Chief Operating Officer, effective July 1, 2024
On June 7, 2024, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christy Oliger to the Board, effective immediately.
On January 8, 2024, Vera Therapeutics, Inc. (the "Company") announced that Celia Lin, M.D., the Company’s Chief Medical Officer, had separated from the Company effective January 3, 2024 (the "Separation Date").
The Company appointed Dr. Robert M. Brenner, M.D., to succeed Dr. Lin as the Company’s Chief Medical Officer, effective January 3, 2024.
Kurt von Emster notified the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) of his resignation as a director of the Company and as Chair of the Board, effective on the date of the Company’s 2022 Annual Meeting of Stockholders.
the Board appointed Michael M. Morrissey, Ph.D., to the Board, to fill the vacancy resulting from Mr. von Emster’s resignation, and to serve as Chair of the Board, effective on the Annual Meeting Date.
On December 10, 2021, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Kimball Hall to the Board, effective immediately.
On July 14, 2021, Vera Therapeutics, Inc. (the “Company”) announced the appointment of Sean P. Grant as the Company’s Chief Financial Officer, effective July 12, 2021 (the “Start Date”).
Max materiality 0.95 · Median 0.62 · Most common event other_material